PACW - Bragar Eagel & Squire P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PacWest Integra and Enviva and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PacWest Bancorp (NASDAQ:PACW), Integra LifeSciences Holdings Corp. (NASDAQ:IART), and Enviva Inc. (NYSE:EVA). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
PacWest Bancorp (NASDAQ:PACW)
Class Period: February 28, 2022 - May 3, 2023
Lead Plaintiff Deadline: November 10, 2023
Throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (i) PacWest had understated the impact of interest rate hikes on PWB, a smaller bank with excessive concentration in specific industries; (ii) accordingly, the Company had overstated the stability and/or sustainability of its deposit base; (iii) as a result, PacWest was exceptionally vulnerable to excessive deposit flows and/or a liquidity crisis; and (iv) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
For more information on the PacWest class action go to: https://bespc.com/cases/PACW
Integra LifeSciences Holdings Corp. (NASDAQ:IART)
Class Period: March 11, 2019 - May 22, 2023
Lead Plaintiff Deadline: November 13, 2023
The claims against Defendants arise from the Company's violations of federal manufacturing regulations governing medical devices, which are intended to protect patients receiving these medical devices from infections and other medical complications. In October 2018, the FDA inspected the Boston Facility and found that Integra was in violation of the good manufacturing practice requirements of the Quality System Regulation. Consequently, on November 2, 2018, the FDA issued a Notice of Inspectional Observations on Form 483 (the "2018 Form 483") to put Integra on notice of those violations. Most significantly, the FDA found that Integra failed to adequately ...